**Core Concept**
Erythropoietin (EPO) is a hormone produced by the kidneys that regulates red blood cell production in the bone marrow. Its production is increased in response to hypoxia, which stimulates the release of erythropoietin.

**Why the Correct Answer is Right**
EPO production is increased in conditions that lead to tissue hypoxia, such as chronic kidney disease (CKD), anemia of chronic disease, and high-altitude exposure. In these conditions, the kidneys sense the decrease in oxygen levels and increase EPO production to stimulate red blood cell production and improve oxygen delivery to tissues. This is mediated by the hypoxia-inducible factor (HIF) pathway, which is activated in response to low oxygen levels.

**Why Each Wrong Option is Incorrect**
**Option A:** While anemia of chronic disease is a condition where EPO production is increased, this option is incomplete and does not provide a clear condition. However, it is a condition where EPO production is indeed increased.

**Option B:** Renal cell carcinoma is a type of kidney cancer, but it is not a condition where EPO production is typically increased. In fact, EPO-producing renal cell carcinomas are a rare type of kidney cancer, and EPO production is not typically increased in this condition.

**Option C:** High-altitude exposure is a condition where EPO production is increased, as the body adapts to the lower oxygen levels at high altitude by increasing red blood cell production.

**Option D:** Anemia of chronic disease is a condition where EPO production is increased, as the body attempts to compensate for the decreased oxygen delivery to tissues.

**Clinical Pearl / High-Yield Fact**
It's worth noting that EPO production can also be increased in other conditions, such as liver disease and pregnancy. Additionally, EPO-producing tumors are a rare but significant cause of secondary polycythemia.

**Correct Answer: B. Renal cell carcinoma is not a condition where EPO production is typically increased.**